Gossamer Bio, Inc. (GOSS) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 11.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -219.32%, forward earnings yield 8.41%. PEG 0.06 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1,980.1 | 0.00 | -1,336.17 | 0.00 | - |
| 2017 | -65.8 | -0.02 | -64.92 | 0.00 | - |
| 2018 | -7.4 | -0.01 | -9.02 | 0.00 | - |
| 2019 | -4.7 | -0.13 | 2.43 | 0.00 | - |
| 2020 | -2.7 | -0.24 | 2.07 | 0.00 | - |
| 2021 | -3.6 | 0.39 | 6.97 | 0.00 | - |
| 2022 | -0.8 | 0.05 | 15.20 | 0.00 | - |
| 2023 | -1.1 | 0.02 | 3.28 | 0.00 | - |
| 2024 | -3.6 | 0.05 | 6.94 | 1.78 | - |
| 2025 | -4.2 | -0.02 | -5.77 | 14.62 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.00 | $0.00 | $-83K | - |
| 2017 | $-0.27 | $0.00 | $-6.77M | - |
| 2018 | $-2.43 | $0.00 | $-146.97M | - |
| 2019 | $-3.30 | $0.00 | $-180.82M | - |
| 2020 | $-3.67 | $0.00 | $-251.58M | - |
| 2021 | $-3.33 | $0.00 | $-249.08M | - |
| 2022 | $-2.84 | $0.00 | $-240.23M | - |
| 2023 | $-1.18 | $0.00 | $-179.82M | - |
| 2024 | $-0.25 | $114.7M | $-56.53M | -49.3% |
| 2025 | $-0.75 | $48.47M | $-170.37M | -351.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.47 | $-0.74 – $-0.19 | $17.62M | $8.9M – $28.93M | 7 |
| 2027 | $-0.16 | $-0.39 – $0.02 | $57.2M | $18.11M – $102.68M | 6 |
| 2028 | $0.05 | $-0.40 – $0.48 | $133.06M | $133.06M – $133.06M | 6 |
| 2029 | $0.17 | $0.03 – $0.36 | $234.44M | $83.35M – $431.86M | 4 |
| 2030 | $0.34 | $0.05 – $0.71 | $362.1M | $128.74M – $667.03M | 2 |
